• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

呼吸道合胞病毒融合基因的分子进化，加拿大，2006-2010 年。

Molecular evolution of respiratory syncytial virus fusion gene, Canada, 2006-2010.

机构信息

McGill University Health Centre, Montréal, Québec, Canada.

出版信息

Emerg Infect Dis. 2012 Jan;18(1):120-4. doi: 10.3201/eid1801.110515.

DOI:10.3201/eid1801.110515
PMID:22264682
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3310097/
Abstract

To assess molecular evolution of the respiratory syncytial virus (RSV) fusion gene, we analyzed RSV-positive specimens from 123 children in Canada who did or did not receive RSV immunoprophylaxis (palivizumab) during 2006-2010. Resistance-conferring mutations within the palivizumab binding site occurred in 8.7% of palivizumab recipients and none of the nonrecipients.

摘要

为评估呼吸道合胞病毒（RSV）融合基因的分子进化，我们分析了 2006 年至 2010 年期间加拿大 123 名接受或未接受 RSV 免疫预防（帕利珠单抗）的 RSV 阳性患儿的标本。帕利珠单抗结合部位的耐药相关突变仅发生于 8.7%的帕利珠单抗接受者，而未接受者均无此突变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30a/3310097/ea3b1380c75b/11-0515-F.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30a/3310097/ea3b1380c75b/11-0515-F.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30a/3310097/ea3b1380c75b/11-0515-F.jpg

相似文献

1
Molecular evolution of respiratory syncytial virus fusion gene, Canada, 2006-2010.呼吸道合胞病毒融合基因的分子进化，加拿大，2006-2010 年。
Emerg Infect Dis. 2012 Jan;18(1):120-4. doi: 10.3201/eid1801.110515.
2
Detection of respiratory syncytial virus fusion protein variants between 2009 and 2012 in China.检测 2009 年至 2012 年期间中国呼吸道合胞病毒融合蛋白变异体。
Arch Virol. 2014 May;159(5):1089-98. doi: 10.1007/s00705-013-1870-9. Epub 2013 Dec 3.
3
Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis.据报告接受帕利珠单抗免疫预防的感染呼吸道合胞病毒儿童的分子特征分析。
J Clin Virol. 2015 Apr;65:26-31. doi: 10.1016/j.jcv.2015.01.016. Epub 2015 Jan 24.
4
Analysis of respiratory syncytial virus fusion protein from clinical isolates of Korean children in palivizumab era, 2009-2015.分析 2009-2015 年韩国儿童在帕利珠单抗时代临床分离株中的呼吸道合胞病毒融合蛋白。
J Infect Chemother. 2019 Jul;25(7):514-519. doi: 10.1016/j.jiac.2019.02.013. Epub 2019 Mar 15.
5
Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab.呼吸道合胞病毒（RSV）融合蛋白中的自然多态性和耐药相关突变：对帕利珠单抗治疗 RSV 易感性的影响。
J Infect Dis. 2012 Feb 15;205(4):635-8. doi: 10.1093/infdis/jir790. Epub 2011 Dec 19.
6
[Research Progress in Membrane Fusion of the Respiratory Syncytial Virus].[呼吸道合胞病毒膜融合的研究进展]
Bing Du Xue Bao. 2015 Sep;31(5):565-72.
7
Cell fusion assay by expression of respiratory syncytial virus (RSV) fusion protein to analyze the mutation of palivizumab-resistant strains.通过呼吸道合胞病毒（RSV）融合蛋白表达进行细胞融合试验，以分析帕利珠单抗耐药株的突变情况。
J Virol Methods. 2016 May;231:48-55. doi: 10.1016/j.jviromet.2016.01.003. Epub 2016 Jan 12.
8
Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein.逃避免疫中和作用是由呼吸道合胞病毒特异性中和单克隆抗体帕利珠单抗与融合蛋白结合的速率变化驱动的。
Virology. 2014 Apr;454-455:139-44. doi: 10.1016/j.virol.2014.02.010. Epub 2014 Mar 3.
9
Respiratory syncytial virus subtype ON1/NA1/BA9 predominates in hospitalized children with lower respiratory tract infections.呼吸道合胞病毒ON1/NA1/BA9亚型在住院的下呼吸道感染儿童中占主导地位。
J Med Virol. 2017 Feb;89(2):213-221. doi: 10.1002/jmv.24619. Epub 2016 Jul 6.
10
Replacement and positive evolution of subtype A and B respiratory syncytial virus G-protein genotypes from 1997-2012 in South Africa.南非 1997-2012 年 A、B 型呼吸道合胞病毒 G 蛋白基因型的替换和正选择进化。
J Infect Dis. 2013 Dec 15;208 Suppl 3:S227-37. doi: 10.1093/infdis/jit477.

引用本文的文献

1
Epidemiological and phylogenetic characterization of human respiratory syncytial virus associated with severe acute respiratory infections in paediatric patients from 2016 to 2023 in Hangzhou, China.2016年至2023年中国杭州儿科患者中与严重急性呼吸道感染相关的人呼吸道合胞病毒的流行病学和系统发育特征
Microb Genom. 2025 Aug;11(8). doi: 10.1099/mgen.0.001484.
2
Molecular characterization of human respiratory syncytial virus in Mexico (season 2023-2024) through whole-genome sequencing.通过全基因组测序对墨西哥2023 - 2024年流行季的人呼吸道合胞病毒进行分子特征分析。
Sci Rep. 2025 Jul 28;15(1):27382. doi: 10.1038/s41598-025-13061-9.
3

本文引用的文献

1
Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.对呼吸道合胞病毒临床前及临床变体的分析，这些变体对单克隆抗体帕利珠单抗和/或莫他珠单抗的中和作用具有抗性。
J Infect Dis. 2011 Mar 1;203(5):674-82. doi: 10.1093/infdis/jiq100. Epub 2011 Jan 5.
2
Palivizumab-resistant human respiratory syncytial virus infection in infancy.婴儿期人呼吸道合胞病毒耐药感染。
Clin Infect Dis. 2010 Jul 15;51(2):185-8. doi: 10.1086/653534.
3
Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.
The Cumulative Variations of Respiratory Syncytial Virus Fusion Protein (F) in Ten Consecutive Years in China.
中国连续十年呼吸道合胞病毒融合蛋白（F）的累积变异情况
Infect Dis Rep. 2024 Oct 17;16(5):1017-1029. doi: 10.3390/idr16050081.
4
EDP-938 Has a High Barrier to Resistance in Healthy Adults Experimentally Infected with Respiratory Syncytial Virus.EDP-938对实验性感染呼吸道合胞病毒的健康成年人具有高耐药屏障。
J Infect Dis. 2025 Feb 20;231(2):e290-e298. doi: 10.1093/infdis/jiae471.
5
Respiratory Syncytial Virus in Adult Patients at a Tertiary Care Hospital in Germany: Clinical Features and Molecular Epidemiology of the Fusion Protein in the Severe Respiratory Season of 2022/2023.德国一家三级保健医院成人患者中的呼吸道合胞病毒：2022/2023 年严重呼吸道季节中融合蛋白的临床特征和分子流行病学。
Viruses. 2024 Jun 12;16(6):943. doi: 10.3390/v16060943.
6
Whole-Genome Sequencing and Genetic Diversity of Human Respiratory Syncytial Virus in Patients with Influenza-like Illness in Sicily (Italy) from 2017 to 2023.2017 年至 2023 年意大利西西里流感样疾病患者中人类呼吸道合胞病毒的全基因组测序和遗传多样性。
Viruses. 2024 May 26;16(6):851. doi: 10.3390/v16060851.
7
Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus.两组人呼吸道合胞病毒病毒种群在宿主内的不同模式。
Nat Commun. 2021 Aug 26;12(1):5125. doi: 10.1038/s41467-021-25265-4.
8
Global molecular diversity of RSV - the "INFORM RSV" study.呼吸道合胞病毒（RSV）的全球分子多样性 - “INFORM RSV”研究。
BMC Infect Dis. 2020 Jun 26;20(1):450. doi: 10.1186/s12879-020-05175-4.
9
Palivizumab and prevention of childhood respiratory syncytial viral infection: protocol for a systematic review and meta-analysis of breakthrough infections.帕利珠单抗与儿童呼吸道合胞病毒感染的预防：突破性感染的系统评价和荟萃分析方案。
BMJ Open. 2019 Jul 23;9(7):e029832. doi: 10.1136/bmjopen-2019-029832.
10
Detection of ON1 and novel genotypes of human respiratory syncytial virus and emergence of palivizumab resistance in Lebanon.黎巴嫩人类呼吸道合胞病毒 ON1 型和新型别及其帕利珠单抗耐药性的出现。
PLoS One. 2019 Feb 21;14(2):e0212687. doi: 10.1371/journal.pone.0212687. eCollection 2019.
呼吸道合胞病毒中和单克隆抗体 motavizumab 和 palivizumab 抑制融合。
J Virol. 2010 Aug;84(16):8132-40. doi: 10.1128/JVI.02699-09. Epub 2010 Jun 2.
4
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.全球儿童因呼吸道合胞病毒导致的急性下呼吸道感染负担：系统评价和荟萃分析。
Lancet. 2010 May 1;375(9725):1545-55. doi: 10.1016/S0140-6736(10)60206-1.
5
From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.美国儿科学会：政策声明——关于使用帕利珠单抗预防呼吸道合胞病毒感染的修订建议。
Pediatrics. 2009 Dec;124(6):1694-701. doi: 10.1542/peds.2009-2345. Epub 2009 Sep 7.
6
Comparison of automated microarray detection with real-time PCR assays for detection of respiratory viruses in specimens obtained from children.用于检测儿童呼吸道病毒的自动化微阵列检测与实时荧光定量PCR检测方法的比较。
J Clin Microbiol. 2009 Mar;47(3):743-50. doi: 10.1128/JCM.01297-08. Epub 2009 Jan 21.
7
Human respiratory syncytial virus and other viral infections in infants receiving palivizumab.接受帕利珠单抗治疗的婴儿中的人呼吸道合胞病毒及其他病毒感染
J Clin Virol. 2008 May;42(1):52-7. doi: 10.1016/j.jcv.2007.11.012. Epub 2008 Feb 27.
8
Genetic variability of the fusion protein and circulation patterns of genotypes of the respiratory syncytial virus.呼吸道合胞病毒融合蛋白的遗传变异性及基因型的流行模式
J Med Virol. 2007 Jun;79(6):820-8. doi: 10.1002/jmv.20891.
9
Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons.两个冬季中住院儿童人群中人类呼吸道合胞病毒基因型的分布及其临床影响
J Infect Dis. 2006 Jan 1;193(1):54-8. doi: 10.1086/498526. Epub 2005 Nov 18.
10
Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants.呼吸道合胞病毒突变体对棉鼠中帕利珠单抗产生的可变抗性。
J Infect Dis. 2004 Dec 1;190(11):1941-6. doi: 10.1086/425515. Epub 2004 Oct 27.